Business
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
FEATURED STORIES
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
With the last full week before the Thanksgiving week in the U.S., companies had a fair amount of clinical trial news. Here’s a look.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Gilead Sciences announced it exercised its options to three of Arcus Biosciences’ programs. Two are anti-TIGIT molecules, domvanalimab and AB308, and the other is etrumadenant and quemliclustat.
Two weeks after Novartis announced it would sell its nearly one-third voting stake in next-door neighbor Roche, investors are chomping at the bit to find out how that almost $21 billion will be put to work.
Based on BridgeBio’s current pipeline of programs, this total amount will be sufficient to carry over 30 drug development and discovery programs well into 2024.
Avilar Therapeutics officially joined the game with $60 million in seed financing from RA Capital Management.
The Richard King Mellon Foundation has awarded a $100 million gift to the University of Pittsburgh and approved a $150 million grant for Carnegie Mellon University.
Novo Nordisk and Dicerna are no strangers. The companies have been collaborating on the development of RNAi therapies for liver disease for the past three years.
The strategic collaboration entails a $180 million equity investment into Owkin and a total payment of $90 million over the next three years, in addition to milestone-based fees to be determined later.
Her career as a physician and scientist is guided by a combination of logic and creativity.